Advances in meningioma genomics, proteomics, and epigenetics: insights into biomarker identification and targeted therapies
Metrics: PDF 212 views | Full Text 358 views | ?
Ahmad A. Nazem1,*, Jacob Ruzevick1,* and Manuel J. Ferreira Jr1
1 Department of Neurosurgery, University of Washington School of Medicine, University of Washington Medical Center, Seattle, WA, 98195, USA
* These authors contributed equally to this work
|Manuel J. Ferreira Jr,||email:||email@example.com|
Keywords: meningioma; skull base; NGS; sequencing; biomarker
Received: October 21, 2020 Accepted: November 03, 2020 Published: December 08, 2020
Meningiomas are a heterogeneous group of tumors, defined histo-pathologically by World Health Organization (WHO) grading. The WHO grade of meningiomas does not always correlate with clinical aggressiveness. Despite maximal surgical resection and adjuvant radiation, a subset of tumors are clinically aggressive; displaying early recurrence and invasion. Current methods for identifying aggressive meningiomas solely focus on genomics, proteomics, or epigenetics and not a combination of all for developing a real-time clinical biomarker. Improved methods for the identification of these outlying tumors can facilitate better classification and potentially adjuvant treatment planning. Understanding the pathways of oncogenesis using multiple markers driving aggressive meningiomas can provide a foundation for targeted therapies, which currently do not exist.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.